# Oragenics Inc: overview OGEN · NYSE · CIK 1174940 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/ogen.md) · [Financials](/companies/ogen/financials.md) · [Filings](/companies/ogen/filings.md) · [Insiders](/companies/ogen/insiders.md) Latest reported revenue: [$0](/filings/0001493152-25-010389.md) for Q4 FY2023, three months to 2023-12-31, from the 10-K filed Mar 14, 2025 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001493152-25-010389). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(11.32)](/filings/0001493152-25-021257.md) | not reported | [(3.65)](/filings/0001493152-26-021967.md) | [(3.10)](/filings/0001493152-26-037749.md) | [(1.96)](/filings/0001493152-25-021257.md) | not reported | [(0.51)](/filings/0001493152-26-021967.md) | [(0.57)](/filings/0001493152-26-037749.md) | | Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [0.1](/filings/0001493152-23-012617.md) | [0.1](/filings/0001493152-24-011979.md) | [0.0](/filings/0001493152-25-010389.md) | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(18130.3%)](/filings/0001493152-23-012617.md) | [(10964.6%)](/filings/0001493152-24-011979.md) | [(55519.9%)](/filings/0001493152-25-010389.md) | not reported | not reported | | Net margin | % | [(18062.0%)](/filings/0001493152-23-012617.md) | [(10864.0%)](/filings/0001493152-24-011979.md) | [(54858.1%)](/filings/0001493152-25-010389.md) | not reported | not reported | | Diluted EPS | $ per share | [(0.14)](/filings/0001493152-22-007664.md) | [(7.11)](/filings/0001493152-24-011979.md) | [(9.18)](/filings/0001493152-25-010389.md) | [(47.88)](/filings/0001493152-26-010282.md) | [(4.56)](/filings/0001493152-26-010282.md) | | Free cash flow | $m | [(13.5)](/filings/0001493152-23-012617.md) | [(15.4)](/filings/0001493152-24-011979.md) | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareBasicAndDiluted; Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/ogen/insiders.md) | Date | Insider | Role | Transaction | Shares | Reported price | Value | Filing | | --- | --- | --- | --- | ---: | ---: | ---: | --- | | 2025-06-18 | [Odyssey Health, Inc.](/insiders/1626644.md) | 10% owner | Sale (S) | 5,044 | $4.26 | $21.5k | [Form 4](/filings/0001683168-25-004612.md) | | 2025-06-17 | [Odyssey Health, Inc.](/insiders/1626644.md) | 10% owner | Sale (S) | 2,000 | $4.46 | $8.9k | [Form 4](/filings/0001683168-25-004612.md) | | 2025-06-16 | [Odyssey Health, Inc.](/insiders/1626644.md) | 10% owner | Sale (S) | 5,000 | $4.45 | $22.3k | [Form 4](/filings/0001683168-25-004526.md) | | 2025-06-13 | [Odyssey Health, Inc.](/insiders/1626644.md) | 10% owner | Sale (S) | 5,000 | $4.27 | $21.3k | [Form 4](/filings/0001683168-25-004526.md) | ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $13.8k | 23,685 | | Reduced −41,387 | | [25 LLC](/funds/1968777.md) | 2026-06-30 | $13.4k | 23,160 | | New +23,160 | | [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $7.4k | 12,771 | | New +12,771 | | [Tower Research Capital LLC (TRC)](/funds/1533421.md) | 2026-06-30 | $2.6k | 4,548 | | Unchanged | | [St. Johns Investment Management Company, LLC](/funds/1605522.md) | 2026-06-30 | $1.1k | 1,924 | | Added +1,724 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $408 | 703 | | Unchanged | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $373 | 642 | | Reduced −4,563 | | [HARBOUR INVESTMENTS, INC.](/funds/810121.md) | 2026-06-30 | $20 | 34 | | Unchanged | | [WELLS FARGO & COMPANY/MN](/funds/72971.md) | 2026-06-30 | $20 | 34 | | Unchanged | | [SBI Securities Co., Ltd.](/funds/1851815.md) | 2026-06-30 | $13 | 23 | | Added +12 | ## Recent filings [All 924 filings](/companies/ogen/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-16 | 04:30 ET | [8-K](/filings/0001493152-26-042843.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-042843 | | 2026-08-28 | 13:06 ET | [8-K](/filings/0001493152-26-040645.md) | 3.01 Delisting notice; 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-040645 | | 2026-08-13 | 16:05 ET | [10-Q](/filings/0001493152-26-037749.md) | Quarterly report, period 2026-06-30 | 0001493152-26-037749 | | 2026-07-06 | 16:05 ET | [8-K](/filings/0001493152-26-032155.md) | 1.01 Entry into a material agreement; 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001493152-26-032155 | | 2026-05-20 | 16:05 ET | [DEF 14A](/filings/0001493152-26-024602.md) | Proxy statement, period 2026-05-20 | 0001493152-26-024602 | | 2026-05-19 | 08:38 ET | [8-K](/filings/0001493152-26-024363.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-024363 | | 2026-05-08 | 16:01 ET | [10-Q](/filings/0001493152-26-021967.md) | Quarterly report, period 2026-03-31 | 0001493152-26-021967 | | 2026-05-07 | 08:15 ET | [8-K](/filings/0001493152-26-021627.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-021627 | | 2026-04-13 | 08:30 ET | [8-K](/filings/0001493152-26-016294.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-016294 | | 2026-03-31 | 16:05 ET | [8-K](/filings/0001493152-26-014128.md) | 5.08 Item not in the standard list; 9.01 Financial statements and exhibits | 0001493152-26-014128 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001493152-26-010282.md), filed Mar 16, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1174940 - Tickers: OGEN - Exchange: NYSE - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: FL - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:35 ET. No prices; not investment advice.